全文获取类型
收费全文 | 35645篇 |
免费 | 1399篇 |
国内免费 | 702篇 |
专业分类
耳鼻咽喉 | 620篇 |
儿科学 | 819篇 |
妇产科学 | 449篇 |
基础医学 | 1065篇 |
口腔科学 | 536篇 |
临床医学 | 2957篇 |
内科学 | 4428篇 |
皮肤病学 | 585篇 |
神经病学 | 2003篇 |
特种医学 | 852篇 |
外科学 | 5368篇 |
综合类 | 6577篇 |
预防医学 | 2089篇 |
眼科学 | 540篇 |
药学 | 4159篇 |
50篇 | |
中国医学 | 2240篇 |
肿瘤学 | 2409篇 |
出版年
2024年 | 14篇 |
2023年 | 414篇 |
2022年 | 1063篇 |
2021年 | 1256篇 |
2020年 | 1217篇 |
2019年 | 1143篇 |
2018年 | 1207篇 |
2017年 | 924篇 |
2016年 | 1183篇 |
2015年 | 1198篇 |
2014年 | 3062篇 |
2013年 | 2880篇 |
2012年 | 2654篇 |
2011年 | 2898篇 |
2010年 | 2506篇 |
2009年 | 2041篇 |
2008年 | 1896篇 |
2007年 | 1749篇 |
2006年 | 1453篇 |
2005年 | 1220篇 |
2004年 | 1032篇 |
2003年 | 947篇 |
2002年 | 771篇 |
2001年 | 699篇 |
2000年 | 474篇 |
1999年 | 364篇 |
1998年 | 288篇 |
1997年 | 181篇 |
1996年 | 145篇 |
1995年 | 111篇 |
1994年 | 99篇 |
1993年 | 74篇 |
1992年 | 57篇 |
1991年 | 46篇 |
1990年 | 41篇 |
1989年 | 34篇 |
1988年 | 38篇 |
1987年 | 32篇 |
1986年 | 26篇 |
1985年 | 67篇 |
1984年 | 41篇 |
1983年 | 29篇 |
1982年 | 24篇 |
1981年 | 16篇 |
1980年 | 37篇 |
1979年 | 28篇 |
1978年 | 10篇 |
1977年 | 7篇 |
1974年 | 7篇 |
1972年 | 12篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
71.
甲状腺结节是指甲状腺细胞在局部异常生长所引起的散在病变。5%~15%的甲状腺结节为恶性。结合现代医疗,仝小林教授在传承传统辨证论治模式,又开启了“分类、分期、分证”的辨证辨病思想,系统阐述甲状腺结节及甲状腺癌的类型、发展及转归等内容,并构建基于甲状腺结节及甲状腺癌分类、分期(根据自然演变过程可以分为郁、瘀、虚3期)、分证思想体系指导下的甲状腺结节及甲状腺癌防治临床实践。分类、分期、分证思想综合考量疾病共性及患者个性,可为现代慢性病中医理论构建提供启示。 相似文献
72.
Given that the global population of elderly individuals is expanding and the difficulty of recovery, hip fractures will be a huge challenge and a critical health issue for all of humanity. Although people have spent more time at home during the coronavirus disease 2019 (COVID-19) pandemic, hip fractures show no sign of abating. Extensive studies have shown that patients with hip fracture and COVID-19 have a multifold increase in mortality compared to those uninfected and a more complex clinical condition. At present, no detailed research has systematically analyzed the relationship between these two conditions and proposed a comprehensive solution. This article aims to systematically review the impact of COVID-19 on hip fracture and provide practical suggestions. We found that hip fracture patients with COVID-19 have higher mortality rates and more complicated clinical outcomes. Indirectly, COVID-19 prevents hip fracture patients from receiving regular medical treatment. With regard to the problems we encounter, we provide clinical recommendations based on existing research evidence and a clinical flowchart for the management of hip fracture patients who are COVID-19 positive. Our study will help clinicians adequately prepare in advance when dealing with such patients and optimize treatment decisions. 相似文献
73.
Jay Pravda 《World journal of gastroenterology : WJG》2022,28(31):4263-4298
In this comprehensive evidence-based analysis of ulcerative colitis (UC), a causal role is identified for colonic epithelial hydrogen peroxide (H2O2) in both the path ogenesis and relapse of this debilitating inflammatory bowel disease. Studies have shown that H2O2 production is significantly increased in the non-inflamed colonic epithelium of individuals with UC. H2O2 is a powerful neutrophilic chemo tactic agent that can diffuse through colonic epithelial cell membranes creating an interstitial chemotactic molecular “trail” that attracts adjacent intra vascular neutrophils into the colonic epithelium leading to mucosal inflammation and UC. A novel therapy aimed at removing the inappropriate H2O2 mediated chemotactic signal has been highly effective in achieving complete histologic resolution of colitis in patients experiencing refractory disease with at least one (biopsy-proven) histologic remission lasting 14 years to date. The evidence implies that therapeutic intervention to prevent the re-establishment of a pathologic H2O2 mediated chemotactic signaling gradient will indefinitely preclude neutrophilic migration into the colonic epithelium constituting a functional cure for this disease. Cumulative data indicate that individuals with UC have normal immune systems and current treatment guidelines calling for the suppression of the immune response based on the belief that UC is caused by an underlying immune dysf unction are not supported by the evidence and may cause serious adverse effects. It is the aim of this paper to present experimental and clinical evidence that identifies H2O2 produced by the colonic epithelium as the causal agent in the pathogenesis of UC. A detailed explanation of a novel therapeutic intervention to normalize colonic H2O2, its rationale, components, and formulation is also provided. 相似文献
74.
【摘要】 目的 回顾分析奥马珠单抗治疗慢性自发性荨麻疹(CSU)的疗效、安全性及停药复发情况。方法 回顾北京大学第一医院皮肤科门诊2018年2月至2021年1月使用奥马珠单抗治疗的CSU病例,分析其临床特征,采用门诊随访形式,通过荨麻疹控制评分(UCT)、皮肤病生活质量指数(DLQI)评估疾病严重程度,监测不良事件及停药后复发情况。正态分布的计量资料组间比较采用独立样本t检验或方差分析,非正态分布的计量资料组间比较采用Mann-Whitney U检验、Wilcoxon符号秩和检验或Kruskal-Wallis H检验,计数资料组间比较采用卡方检验或Fisher 精确检验。结果 纳入59例CSU患者,奥马珠单抗治疗至少3个月,其中45例治疗达6个月,15例达12个月。经奥马珠单抗治疗,UCT从基线期3.0(1.0,6.0)分上升至第1个月11.0 (3.0,14.0)分和第3个月15.0 (12.0,16.0)分(均P < 0.05)。DLQI从基线期16.0(12.0,20.0)分下降至第1个月7.0 (1.0,13.0)分和第3个月1.0 (0.0,4.0)分(均P < 0.05)。疾病部分或完全控制的比例在基线期为0,第1个月上升至44.1%,第3个月达78.0%,第6个月达88.9%。疾病对生活质量存在重度或极重度影响的比例在基线期为84.7%,第1个月降至30.5%,第3个月降至15.3%,第6个月降至4.4%。对奥马珠单抗治疗完全反应组和部分反应组比无反应组病程更短(t = -2.894,P = 0.011;t = -2.511,P = 0.036);完全反应组比部分反应组和无反应组治疗时间更长(t = 2.479,P = 0.039;t = 2.677,P = 0.022)。慢反应组与快反应组相比,基线DLQI更高(Z = -2.622,P = 0.009),基线UCT更低(Z = -2.746,P = 0.006)。19例患者病情完全控制后停药,其中13例(68.4%)在停药7(5,8)周后复发,复发后UCT评分高于治疗前(Z = 3.172,P = 0.001),复发组比未复发组病程更长(Z = -2.635,P = 0.007)。复发后5例重新开始奥马珠单抗治疗,均再次得到部分或完全控制。治疗期间报告不良反应事件均为轻中度。结论 奥马珠单抗能够有效控制CSU症状,提高患者生活质量,且安全性较好,但停药后复发率高,复发后重新开始奥马珠单抗治疗仍有效。 相似文献
75.
在真实世界中应用银杏叶滴丸治疗冠心病、脑梗死的基础上,对其合并用药信息采用社区发现算法(Louvain算法)进行复杂网络分析,挖掘其合并用药规律。在冠心病的临床用药方面,银杏叶滴丸常合并应用的西药主要有阿司匹林、氯吡格雷、阿托伐他汀、氨氯地平、单硝酸异山梨酯等,合并应用的中药以注射用灯盏花素、注射用丹参多酚酸盐为主;其合并用药组合主要有阿司匹林 + 单硝酸异山梨酯/阿托伐他汀/氨氯地平/曲美他嗪、氯吡格雷 + 注射用丹参多酚酸盐/匹伐他汀/氨氯地平/阿托伐他汀、阿托伐他汀 + 氨氯地平。在脑梗死的联合用药方面,银杏叶滴丸常合并应用的西药主要有阿司匹林、阿托伐他汀、氨氯地平、氯吡格雷、硝苯地平等,合并应用的中药以注射用灯盏花素、疏血通注射液为主;其联合用药组合主要有阿司匹林 + 氨氯地平/阿托伐他汀/疏血通注射液/硝苯地平、阿托伐他汀 + 氯吡格雷/氨氯地平、注射用灯盏花素 + 阿司匹林/奥拉西坦。本研究中的数据来源于真实世界,对临床医生的诊疗具有一定的参考意义。 相似文献
76.
李超明 《实用医学影像杂志》2021,(1)
目的评价恩替卡韦治疗慢性乙型肝炎肝纤维化的疗效,并使用肝脏实时剪切波弹性成像和超声量化评分对疗效进行对比分析。方法选择在2017年10月至2018年3月本院收治的54例慢性乙型肝炎肝纤维化患者,对其进行肝脏实时剪切波弹性成像和超声量化检查,之后对患者实施恩替卡韦治疗,治疗周期为1年,治疗后再次实施肝脏实时剪切波弹性成像和超声量检查,对2次检查的各项指标进行对比,分析检查指标的差异。结果治疗前S1-S3期与S4期超声评分、肝硬度进行对比,差异有统计学意义,治疗后患者超声评分、肝硬度(kPa)指标低于治疗前(P<0.05)。结论恩替卡韦治疗慢性乙型肝炎肝纤维化疗效较为显著,同时在进行病情评估的过程中实施肝脏实时剪切波弹性成像和超声量化评分,可以对肝脏疾病的不同阶段进行分期,检查和治疗的效果均较为理想。 相似文献
77.
78.
Nicolas Mottet Roderick C.N. van den Bergh Erik Briers Thomas Van den Broeck Marcus G. Cumberbatch Maria De Santis Stefano Fanti Nicola Fossati Giorgio Gandaglia Silke Gillessen Nikos Grivas Jeremy Grummet Ann M. Henry Theodorus H. van der Kwast Thomas B. Lam Michael Lardas Matthew Liew Malcolm D. Mason Philip Cornford 《European urology》2021,79(2):243-262
ObjectiveTo present a summary of the 2020 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG) guidelines on screening, diagnosis, and local treatment of clinically localised prostate cancer (PCa).Evidence acquisitionThe panel performed a literature review of new data, covering the time frame between 2016 and 2020. The guidelines were updated and a strength rating for each recommendation was added based on a systematic review of the evidence.Evidence synthesisA risk-adapted strategy for identifying men who may develop PCa is advised, generally commencing at 50 yr of age and based on individualised life expectancy. Risk-adapted screening should be offered to men at increased risk from the age of 45 yr and to breast cancer susceptibility gene (BRCA) mutation carriers, who have been confirmed to be at risk of early and aggressive disease (mainly BRAC2), from around 40 yr of age. The use of multiparametric magnetic resonance imaging in order to avoid unnecessary biopsies is recommended. When a biopsy is performed, a combination of targeted and systematic biopsies must be offered. There is currently no place for the routine use of tissue-based biomarkers. Whilst prostate-specific membrane antigen positron emission tomography computed tomography is the most sensitive staging procedure, the lack of outcome benefit remains a major limitation. Active surveillance (AS) should always be discussed with low-risk patients, as well as with selected intermediate-risk patients with favourable International Society of Urological Pathology (ISUP) 2 lesions. Local therapies are addressed, as well as the AS journey and the management of persistent prostate-specific antigen after surgery. A strong recommendation to consider moderate hypofractionation in intermediate-risk patients is provided. Patients with cN1 PCa should be offered a local treatment combined with long-term hormonal treatment.ConclusionsThe evidence in the field of diagnosis, staging, and treatment of localised PCa is evolving rapidly. The 2020 EAU-EANM-ESTRO-ESUR-SIOG guidelines on PCa summarise the most recent findings and advice for their use in clinical practice. These PCa guidelines reflect the multidisciplinary nature of PCa management.Patient summaryUpdated prostate cancer guidelines are presented, addressing screening, diagnosis, and local treatment with curative intent. These guidelines rely on the available scientific evidence, and new insights will need to be considered and included on a regular basis. In some cases, the supporting evidence for new treatment options is not yet strong enough to provide a recommendation, which is why continuous updating is important. Patients must be fully informed of all relevant options and, together with their treating physicians, decide on the most optimal management for them. 相似文献
79.
80.
《Sleep medicine》2021
ObjectiveRestless legs syndrome (RLS) is a sensorimotor disorder that is characterized by uncomfortable and unpleasant sensations mainly in the legs. Two placebo-controlled studies (Phase II/III and post-marketing) in Japanese patients with RLS failed to demonstrate the efficacy of gabapentin enacarbil (GE) 600 mg in the change from baseline in International Restless Legs Syndrome Rating Scale (IRLS) score at the end of the treatment period. The high response to placebo is thought to be a possible reason why the post-marketing study failed. The objectives of these post hoc analyses were to determine potential predictive factors associated with improvement in IRLS score with GE treatment and to identify subgroups with higher placebo responses.MethodsWe combined data from the two Japanese studies and analyzed change from baseline in IRLS score in the pooled population and subgroups defined by several patient characteristics. Moreover, we calculated the variable importance of each factor and performed predictive enrichment analysis to identify an enrichable subpopulation with greater improvement by GE treatment.ResultsThe post hoc analyses suggested that higher baseline IRLS score (≥21) and higher body mass index (≥25 kg/m2) were associated with higher placebo responses. On the other hand, positive family history of RLS, prior use of dopaminergic receptor agonists, and higher baseline ferritin level (≥50 ng/mL) were associated with higher responses to GE.ConclusionsOur results suggest that patients with typical idiopathic RLS characteristics, including positive family history and no low ferritin level, would be expected to derive the greatest benefits from GE treatment. 相似文献